Anticoagulants

Agents that prevent clotting.
DrugDrug NameDrug Indication
DB00006BivalirudinFor treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
DB00054AbciximabAbciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
DB00266DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
DB00278ArgatrobanArgatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
DB00407ArdeparinFor prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
DB00498PhenindioneFor the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. Also used for anticoagulant prophylaxis.
DB00569FondaparinuxApproved for: (1) prophylaxis of VTE for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement and knee surgery; (2) prophylaxis of VTE patients undergoing abdominal surgery who are at high risk of thromboembolic complications (e.g. patients undergoing abdominal cancer surgery); (3) treatment of acute DVT and PE; (4) management of UA and NSTEMI for the prevention of death and subsequent myocardial infarction (MI); and (5) management of STEMI for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy. Fondaparinux should not be used as the sole anticoagulant during percutaneous coronary intervention (PCI) due to an increased risk of guiding catheter thrombosis.
DB00682WarfarinFor the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.
DB00686Pentosan PolysulfateFor the relief of bladder pain or discomfort associated with interstitial cystitis.
DB00946PhenprocoumonUsed for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).
DB00974Edetic AcidFor the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
DB01109HeparinUnfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.
DB01225EnoxaparinFor the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
DB01418AcenocoumarolFor the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
DB04898XimelagatranFor the treatment of acute deep vein thrombosis.
DB05099AncrodFor the treatment of established deep vein thrombosis; central retinal and branch vein thrombosis; priapism; pulmonary hypertension of embolic origin; embolism after insertion of prosthetic cardiac valves; rethrombosis after thrombolytic therapy and rethrombosis after vascular surgery. It is also indicated for the prevention of deep venous thrombosis after repair of the fractured neck of a femur.
DB06228RivaroxabanRivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).
DB06271SulodexideSulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have also extended its use in venous disease.
DB06406IdraparinuxInvestigated for use/treatment in thrombosis, venous thromboembolism, strokes, heart disease, and atrial fibrillation.
DB06605ApixabanApixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
DB06635OtamixabanInvestigated for use/treatment in thrombosis.
DB06695Dabigatran etexilateDabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.
DB06754DanaparoidIndicated for the prophylaxis of post-operative deep venous thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing elective hip replacement surgery [FDA Label].
DB06779DalteparinDalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes). It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
DB07767Ferulic acidNot Available
DB08794Ethyl biscoumacetateNot Available
DB08813NadroparinNadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.
DB09075EdoxabanEdoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
DB09255DextranDextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration. It is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15% of the blood mass, if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection. Dextran is also used for the prevention of profound postoperative venous thrombosis.[L1455] Dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritations.[L1461]
DB09259ReviparinBy the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients.[L1469]
DB09261CertoparinUsed in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DB11095DesirudinIndicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
DB11268ProtocatechualdehydeNot Available
DB11312Protein CProtein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
DB11598Antithrombin III humanAntithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism
DB11984LetaxabanNot Available
DB12289DarexabanNot Available
DB12598NafamostatUsed as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.
DB12831GabexateNo approved indication.
DB13124TroxerutinNot Available
DB13136FluindioneNot Available
DB13149Protein S humanFor use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors.
DB09125Potassium CitrateFor the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.
DB09154Sodium CitrateUsed as an anticoagulant during plasmophoresis as well as a neutralizing agent in the treatment of upset stomach and acidic urine [FDA Label] [L788] [L789].
DB00031TenecteplaseFor treatment of myocardial infarction and lysis of intracoronary emboli
DB00055Drotrecogin alfaFor reduction of mortality in patients with severe sepsis.
DB04932DefibrotideDefibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others.
DB06822TinzaparinTinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.
DB13646SaruplaseNot Available
DB00086StreptokinaseFor the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
DB00261AnagrelideFor the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
DB00945Acetylsalicylic acidFor use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris.
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB05254FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
DB06543AstaxanthinInvestigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma.
DB00013UrokinaseUrokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
DB00975DipyridamoleFor as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
DB01088IloprostUsed for the treatment of pulmonary arterial hypertension.
DB01240EpoprostenolFor the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
DB05229BeraprostFor the treatment of pulmonary hypertension.
DB06209PrasugrelIndicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding.
DB06441CangrelorFor use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
DB08814TriflusalTriflusal is indicated as prophylaxis of thromboembolic disorders.[L1185] It has been registered in Spain and in other countries of Europe, South America and South Korea for the prevention of Stroke and myocardial infarction.[T93]
DB08816TicagrelorFor the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation.
DB08994DitazoleNot Available
DB09030VorapaxarVorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone.
DB09258BemiparinBemiparin is indicated in the following cases: To prevent blood clots in the veins after general abdominal surgery in patients with a moderate risk of venous thromboembolism; in the prevention of the thromboembolic disease in non-surgical patients; prevention of clotting in the extracorporeal circuit during hemodialysis; to prevent blood clots in the veins after a major orthopedic surgery in patients with high risk of venous thromboembolism; secondary prevention of venous thromboembolism; recurrence in patients with deep vein thrombosis; transient prevention and treatment of deep vein thrombosis (DVT) [L1463].
DB09260ParnaparinUsed in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DB00001LepirudinFor the treatment of heparin-induced thrombocytopenia
DB00009AlteplaseFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
DB00015ReteplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00029AnistreplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB14094TocopherylquinoneNot Available
DB06679AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
DB034104-hydroxycoumarinNot Available
DB08496(R)-warfarinNot Available
DB14055(S)-WarfarinNot Available
DB12364BetrixabanBetrixaban is indicated for prophylaxis of venous thromboembolism (VTE) in conditions of moderate to severe restricted mobility or in patients that qualify as in risk of VTE.
DB14598Edetate calcium disodium anhydrousNot Available
DB11154Zinc citrateNot Available
DB14600Edetate disodium anhydrousFor the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
DB11166Antithrombin AlfaAntithrombin alfa is a recombinant antithrombin it is indicated for the prevention of peri-operative and peri-partum thromboembolic events in patients with hereditary deficiency of antithrombin.
DB04665CoumarinNot Available
DrugDrug NameTargetType
DB00006BivalirudinMyeloperoxidaseenzyme
DB00006BivalirudinProthrombintarget
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00266DicoumarolSerum albumincarrier
DB00266DicoumarolCytochrome P450 2C9enzyme
DB00266DicoumarolCytochrome P450 2C6enzyme
DB00266DicoumarolCytochrome P450 2C11enzyme
DB00266DicoumarolVitamin K epoxide reductase complex subunit 1target
DB00266DicoumarolNAD(P)H dehydrogenase [quinone] 1target
DB00266DicoumarolQuinone oxidoreductasetarget
DB00278ArgatrobanCytochrome P450 3A4enzyme
DB00278ArgatrobanCytochrome P450 3A5enzyme
DB00278ArgatrobanProthrombintarget
DB00407ArdeparinHeparin cofactor 2target
DB00407ArdeparinAntithrombin-IIItarget
DB00498PhenindioneVitamin K epoxide reductase complex subunit 1target
DB00569FondaparinuxAntithrombin-IIItarget
DB00569FondaparinuxCoagulation factor Xtarget
DB00682WarfarinAlpha-1-acid glycoprotein 1carrier
DB00682WarfarinSerum albumincarrier
DB00682WarfarinCytochrome P450 2C8enzyme
DB00682WarfarinCytochrome P450 1A2enzyme
DB00682WarfarinCytochrome P450 2C9enzyme
DB00682WarfarinCytochrome P450 1A1enzyme
DB00682WarfarinCytochrome P450 2C19enzyme
DB00682WarfarinCytochrome P450 3A4enzyme
DB00682WarfarinCytochrome P450 2C18enzyme
DB00682WarfarinVitamin K epoxide reductase complex subunit 1target
DB00682WarfarinNuclear receptor subfamily 1 group I member 2target
DB00686Pentosan PolysulfateFibroblast growth factor 1target
DB00686Pentosan PolysulfateFibroblast growth factor 4target
DB00686Pentosan PolysulfateFibroblast growth factor 2target
DB00946PhenprocoumonAlpha-1-acid glycoprotein 1carrier
DB00946PhenprocoumonSerum albumincarrier
DB00946PhenprocoumonCytochrome P450 2C9enzyme
DB00946PhenprocoumonCytochrome P450 3A4enzyme
DB00946PhenprocoumonCytochrome P450 2C8enzyme
DB00946PhenprocoumonVitamin K epoxide reductase complex subunit 1target
DB00974Edetic AcidAdenosine deaminaseenzyme
DB00974Edetic AcidSerum paraoxonase/lactonase 3enzyme
DB00974Edetic AcidCytochrome P450 19A1enzyme
DB00974Edetic AcidLeadtarget
DB00974Edetic AcidIrontarget
DB00974Edetic AcidManganese cationtarget
DB01109HeparinHeparanaseenzyme
DB01109HeparinAntithrombin-IIItarget
DB01109HeparinCoagulation factor Xtarget
DB01109HeparinP-selectintarget
DB01109HeparinFibroblast growth factor receptor 4target
DB01109HeparinFibroblast growth factor 4target
DB01109HeparinFibroblast growth factor 19target
DB01109HeparinFibroblast growth factor receptor 1target
DB01109HeparinFibroblast growth factor 1target
DB01109HeparinFibroblast growth factor receptor 2target
DB01109HeparinFibroblast growth factor 2target
DB01109HeparinPlatelet factor 4target
DB01109HeparinHepatocyte growth factortarget
DB01225EnoxaparinMyeloperoxidaseenzyme
DB01225EnoxaparinAntithrombin-IIItarget
DB01225EnoxaparinCoagulation factor Xtarget
DB01418AcenocoumarolSerum albumincarrier
DB01418AcenocoumarolAlpha-1-acid glycoprotein 1carrier
DB01418AcenocoumarolCytochrome P450 2C9enzyme
DB01418AcenocoumarolCytochrome P450 1A2enzyme
DB01418AcenocoumarolCytochrome P450 2C19enzyme
DB01418AcenocoumarolCytochrome P450 3A4enzyme
DB01418AcenocoumarolVitamin K epoxide reductase complex subunit 1target
DB04898XimelagatranCytochrome P450 2C9enzyme
DB04898XimelagatranProthrombintarget
DB05099AncrodFibrinogen alpha chaintarget
DB06228RivaroxabanCytochrome P450 3A4enzyme
DB06228RivaroxabanCytochrome P450 2J2enzyme
DB06228RivaroxabanCytochrome P450 3A5enzyme
DB06228RivaroxabanCoagulation factor Xtarget
DB06228RivaroxabanMultidrug resistance protein 1transporter
DB06271SulodexideHeparin cofactor 2target
DB06271SulodexideAntithrombin-IIItarget
DB06406IdraparinuxCoagulation factor Xtarget
DB06605ApixabanCytochrome P450 3A4enzyme
DB06605ApixabanCytochrome P450 1A2enzyme
DB06605ApixabanCytochrome P450 2C8enzyme
DB06605ApixabanCytochrome P450 2C9enzyme
DB06605ApixabanCytochrome P450 2C19enzyme
DB06605ApixabanCytochrome P450 2J2enzyme
DB06605ApixabanCytochrome P450 3A5enzyme
DB06605ApixabanCoagulation factor Xtarget
DB06605ApixabanMultidrug resistance protein 1transporter
DB06605ApixabanATP-binding cassette sub-family G member 2transporter
DB06635OtamixabanCoagulation factor Xtarget
DB06695Dabigatran etexilateLiver carboxylesterase 1enzyme
DB06695Dabigatran etexilateCocaine esteraseenzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 1-9enzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 2B7enzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 2B15enzyme
DB06695Dabigatran etexilateRibosyldihydronicotinamide dehydrogenase [quinone]enzyme
DB06695Dabigatran etexilateProthrombintarget
DB06695Dabigatran etexilateMultidrug resistance protein 1transporter
DB06754DanaparoidAntithrombin-IIItarget
DB06779DalteparinHeparanaseenzyme
DB06779DalteparinVascular endothelial growth factor Atarget
DB06779DalteparinTissue factor pathway inhibitortarget
DB06779DalteparinAntithrombin-IIItarget
DB06779DalteparinP-selectintarget
DB07767Ferulic acidEndo-1,4-beta-xylanase Ytarget
DB07767Ferulic acidEndo-1,4-beta-xylanase Ztarget
DB07767Ferulic acidEst1etarget
DB07767Ferulic acidO-methyltransferasetarget
DB08794Ethyl biscoumacetateGlutamine synthetaseenzyme
DB08794Ethyl biscoumacetateCytochrome P450 3A4enzyme
DB08813NadroparinProto-oncogene c-Fostarget
DB08813NadroparinMyc proto-oncogene proteintarget
DB08813NadroparinP-selectintarget
DB08813NadroparinAntithrombin-IIItarget
DB09075EdoxabanCoagulation factor Xtarget
DB09075EdoxabanMultidrug resistance protein 1transporter
DB11095DesirudinCarboxypeptidase A1enzyme
DB11598Antithrombin III humanAntithrombin-IIItarget
DB12598NafamostatIntercellular adhesion molecule 1target
DB12598NafamostatTrypsin-1target
DB12598NafamostatKallikrein-1target
DB12598NafamostatProthrombintarget
DB12598NafamostatCoagulation factor Xtarget
DB12598NafamostatCoagulation factor XIItarget
DB12598NafamostatSolute carrier family 22 member 1transporter
DB12598NafamostatSolute carrier family 22 member 2transporter
DB12831GabexateTrypsin-1enzyme
DB12831GabexateComplement C1s subcomponentenzyme
DB12831GabexateComplement C1r subcomponentenzyme
DB12831GabexatePlasma kallikreintarget
DB12831GabexateProthrombintarget
DB12831GabexatePlasminogentarget
DB13136FluindioneCytochrome P450 2C9enzyme
DB13136FluindioneCytochrome P450 3A4enzyme
DB13149Protein S humanCoagulation factor Vtarget
DB13149Protein S humanCoagulation factor Xtarget
DB13149Protein S humanVitamin K-dependent protein Ctarget
DB09154Sodium CitrateMitochondrial 2-oxodicarboxylate carriertransporter
DB09154Sodium CitrateSolute carrier family 13 member 2transporter
DB09154Sodium CitrateSolute carrier family 13 member 5transporter
DB09154Sodium CitrateTricarboxylate transport protein, mitochondrialtransporter
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseTetranectintarget
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseCalreticulintarget
DB00031TenecteplaseCalnexintarget
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00031TenecteplasePlasminogentarget
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB04932DefibrotideAdenosine receptor A1target
DB04932DefibrotideAdenosine receptor A2atarget
DB04932DefibrotideAdenosine receptor A2btarget
DB06822TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
DB06822TinzaparinAntithrombin-IIItarget
DB06822TinzaparinIntegrin alpha-4target
DB06822TinzaparinStromal cell-derived factor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB00086StreptokinasePlasminogentarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00261AnagrelideCytochrome P450 1A2enzyme
DB00261AnagrelidecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00945Acetylsalicylic acidSerum albumincarrier
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C8enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidNuclear factor NF-kappa-Btarget
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidSolute carrier family 22 member 7transporter
DB04925DesmoteplasePlasminogentarget
DB05254FibrinolysinPlasminogen activator inhibitor 1target
DB05254FibrinolysinUrokinase-type plasminogen activatortarget
DB06543AstaxanthinNF-kappa-B inhibitor alphatarget
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinasePlasminogentarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseNidogen-1target
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00975DipyridamolecAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10Atarget
DB00975DipyridamolecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00975DipyridamolecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00975DipyridamoleAdenosine deaminasetarget
DB00975DipyridamoleCalcipressin-1target
DB00975DipyridamoleAlpha-1-acid glycoprotein 1target
DB00975DipyridamoleMultidrug resistance-associated protein 4transporter
DB00975DipyridamoleMultidrug resistance-associated protein 5transporter
DB00975DipyridamoleMultidrug resistance protein 1transporter
DB00975DipyridamoleSolute carrier organic anion transporter family member 1B1transporter
DB00975DipyridamoleSolute carrier organic anion transporter family member 1B3transporter
DB00975DipyridamoleSolute carrier organic anion transporter family member 2B1transporter
DB00975DipyridamoleBile salt export pumptransporter
DB01088IloprostProstacyclin receptortarget
DB01088IloprostTissue-type plasminogen activatortarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB01088IloprostProstaglandin E2 receptor EP1 subtypetarget
DB01088IloprostProstaglandin D2 receptor 2target
DB01088IloprostSolute carrier organic anion transporter family member 2B1transporter
DB01088IloprostSolute carrier organic anion transporter family member 2A1transporter
DB01088IloprostSolute carrier organic anion transporter family member 3A1transporter
DB01240EpoprostenolP2Y purinoceptor 12target
DB01240EpoprostenolProstacyclin receptortarget
DB01240EpoprostenolProstacyclin synthasetarget
DB05229BeraprostCytochrome P450 2C8enzyme
DB05229BeraprostProstacyclin receptortarget
DB06209PrasugrelSerum albumincarrier
DB06209PrasugrelCocaine esteraseenzyme
DB06209PrasugrelCytochrome P450 3A4enzyme
DB06209PrasugrelCytochrome P450 2B6enzyme
DB06209PrasugrelCytochrome P450 2C9enzyme
DB06209PrasugrelCytochrome P450 2C19enzyme
DB06209PrasugrelP2Y purinoceptor 12target
DB06441CangrelorP2Y purinoceptor 12target
DB08814TriflusalSerum albumincarrier
DB08814TriflusalProstaglandin G/H synthase 1target
DB08814TriflusalNuclear factor NF-kappa-B p105 subunittarget
DB08814TriflusalNitric oxide synthase, inducibletarget
DB08814TriflusalcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10Atarget
DB08816TicagrelorCytochrome P450 3A4enzyme
DB08816TicagrelorCytochrome P450 2D6enzyme
DB08816TicagrelorCytochrome P450 2C9enzyme
DB08816TicagrelorP2Y purinoceptor 12target
DB08816TicagrelorMultidrug resistance protein 1transporter
DB09030VorapaxarCytochrome P450 3A4enzyme
DB09030VorapaxarCytochrome P450 2J2enzyme
DB09030VorapaxarProteinase-activated receptor 1target
DB09258BemiparinPlasma serine protease inhibitorenzyme
DB09258BemiparinCoagulation factor Xtarget
DB09258BemiparinAntithrombin-IIItarget
DB09258BemiparinHeparin cofactor 2target
DB00001LepirudinProthrombintarget
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogentarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogentarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogentarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB034104-hydroxycoumarinCytochrome P450 3A4enzyme
DB034104-hydroxycoumarinMajor NAD(P)H-flavin oxidoreductasetarget
DB08496(R)-warfarinSerum albumincarrier
DB08496(R)-warfarinCytochrome P450 2C8enzyme
DB08496(R)-warfarinCytochrome P450 2C9enzyme
DB08496(R)-warfarinCytochrome P450 2C18enzyme
DB08496(R)-warfarinCytochrome P450 2C19enzyme
DB08496(R)-warfarinCytochrome P450 1A2enzyme
DB08496(R)-warfarinCytochrome P450 1A1enzyme
DB08496(R)-warfarinCytochrome P450 3A4enzyme
DB14055(S)-WarfarinCytochrome P450 3A4enzyme
DB14055(S)-WarfarinCytochrome P450 2C8enzyme
DB14055(S)-WarfarinCytochrome P450 2C9enzyme
DB14055(S)-WarfarinCytochrome P450 2C18enzyme
DB14055(S)-WarfarinCytochrome P450 2C19enzyme
DB12364BetrixabanProthrombinenzyme
DB12364BetrixabanCoagulation factor Xtarget
DB12364BetrixabanMultidrug resistance protein 1transporter
DB12364BetrixabanPotassium voltage-gated channel subfamily H member 2transporter
DB14600Edetate disodium anhydrousAdenosine deaminaseenzyme
DB14600Edetate disodium anhydrousCytochrome P450 1A2enzyme
DB14600Edetate disodium anhydrousSerum paraoxonase/lactonase 3enzyme
DB14600Edetate disodium anhydrousCytochrome P450 19A1enzyme
DB14600Edetate disodium anhydrousLeadtarget
DB14600Edetate disodium anhydrousIrontarget
DB14600Edetate disodium anhydrousManganese cationtarget
DB11166Antithrombin AlfaProthrombintarget
DB11166Antithrombin AlfaCoagulation factor Xtarget
DB04665CoumarinCytochrome P450 2C9enzyme
DB04665CoumarinCytochrome P450 2A6target